 "Suven Life soars on securing patents in US, New Zealand")
Shares of Suven Life Sciences has soared 19% to Rs 296, also its new high on BSE, after the biopharmaceutical company said it has secured patents in the US and New Zealand.
“The company secured patents in USA and New Zealand to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist and these patents are valid until 2030 and 2031 respectively,” Suven Life Sciences said in news release.
These therapeutic agents are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, the company said.
With these new patents, Suven has a total of 20 granted patents from US and 23 granted patents from New Zealand.
The stock opened at Rs 250 and touched a low of Rs 243 on BSE in early morning trade. The counter has seen huge trading volumes with a combined 8.77 million shares changed hands till 1511 hours against an average sub 2 million shares that were traded daily in past two-weeks on BSE and NSE.
“The company secured patents in USA and New Zealand to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist and these patents are valid until 2030 and 2031 respectively,” Suven Life Sciences said in news release.
These therapeutic agents are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, the company said.
With these new patents, Suven has a total of 20 granted patents from US and 23 granted patents from New Zealand.
The stock opened at Rs 250 and touched a low of Rs 243 on BSE in early morning trade. The counter has seen huge trading volumes with a combined 8.77 million shares changed hands till 1511 hours against an average sub 2 million shares that were traded daily in past two-weeks on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%